BofA analyst Jason Zemansky raised the firm’s price target on Keros Therapeutics (KROS) to $19 from $18 and keeps a Neutral rating on the shares after adjusting projections following the company’s Q3 earnings update.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KROS:
- Keros Therapeutics price target raised to $27 from $23 at Oppenheimer
- Promising Future for Keros Therapeutics: Buy Rating Backed by Strategic Focus and Key Partnerships
- Keros Therapeutics Reports Strong Revenue Growth
- Keros Therapeutics: Hold Rating Amid Strategic Focus on KER-065 and Financial Uncertainties
- Keros Therapeutics: Strategic Focus on KER-065 and Financial Position Justifies Hold Rating